Alexion Pharmaceuticals

2009 Archives

Soliris(R) Reduced Hemolysis, Lowered Thrombosis Rate and Improved Quality of Life in Patients with PNH Who Had Previously Never Been Transfused

Monday, December 7, 2009
^® Reversed Thrombocytopenia in Patients with Both PNH and Pre-Existing Thrombocytopenia in Study Presented at ASH Annual Meeting"> Soliris^® Reversed Thrombocytopenia in Patients with Both PNH and Pre-Existing Thrombocytopenia in Study Presented at ASH Annual Meeting

Monday, December 7, 2009
Soliris(R) Reduced Hemolysis, Decreased Transfusion Requirements and Improved Fatigue in Patients with PNH and Bone Marrow Insufficiency Disorders

Sunday, December 6, 2009
Researchers Report Clinical Association Between Type II PNH Cells and Thrombocytopenia

Sunday, December 6, 2009
Long-Term Soliris(R) Treatment Resulted in Sustained Reduction in Hemolysis and Improved Kidney Function in Japanese Patients with PNH

Saturday, December 5, 2009
Alexion Reports Progress on Commissioning of Rhode Island Manufacturing Facility as Second Source of Supply

Wednesday, December 2, 2009
Alexion Appoints William R. Keller to its Board of Directors

Tuesday, December 1, 2009
Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference

Wednesday, November 11, 2009
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the ASH Annual Meeting

Tuesday, November 10, 2009
Alexion to Present at Credit Suisse's 2009 Healthcare Conference

Thursday, November 5, 2009
Alexion to Present at the Oppenheimer 20th Annual Healthcare Conference

Wednesday, October 28, 2009
Alexion Reports Third Quarter 2009 Results

Thursday, October 22, 2009
Alexion Pharmaceuticals to Report Third Quarter 2009 Results on October 22, 2009

Monday, October 12, 2009
Alexion to Present at the UBS Global Life Sciences Conference

Wednesday, September 16, 2009
Alexion to Present at Investor Conferences

Tuesday, September 8, 2009
^® (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)"> European Commission and U.S. FDA Grant Alexion's Soliris^® (eculizumab) Orphan Drug Designation for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)

Thursday, August 6, 2009
Alexion Reports Second Quarter 2009 Results

Thursday, July 23, 2009
Alexion Pharmaceuticals to Report Second Quarter 2009 Results on July 23, 2009

Thursday, July 9, 2009
Alexion Extends Its Commitment to a Green Footprint Through Its Ambitious New Solar Energy System

Friday, June 19, 2009
Alexion to Present at the Jefferies & Co. 3rd Annual Healthcare Conference

Wednesday, June 10, 2009
Alexion's Soliris(R) Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease

Wednesday, June 10, 2009
New Research Presented at EHA Congress Shows That Soliris(R) Significantly Reduced Hemolysis in Never-Transfused Patients with PNH

Sunday, June 7, 2009
Alexion to Present at Investor Conferences

Wednesday, June 3, 2009
New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes

Friday, May 29, 2009
Researchers to Report on the Investigational Use of Alexion's Soliris(R) (Eculizumab) to Prevent Antibody-Mediated Rejection in High-Risk Kidney Transplant Patients

Thursday, May 28, 2009
Alexion Reports First Quarter 2009 Results

Thursday, April 23, 2009
Alexion Pharmaceuticals to Report First Quarter 2009 Results on April 23, 2009

Thursday, April 9, 2009
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH

Wednesday, April 1, 2009
Alexion to Present at the 4th Annual Citi Biotech Day

Wednesday, March 25, 2009
Alexion to Present at the Cowen and Company 29th Annual Health Care Conference

Wednesday, March 11, 2009
Alexion Joins NORD and EURORDIS in Supporting the Goals of Rare Disease Day

Friday, February 27, 2009
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH

Wednesday, February 25, 2009
Alexion Reports Fourth Quarter and Full Year 2008 Results

Thursday, February 12, 2009
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Canada for All Patients with PNH

Thursday, January 29, 2009
New England Journal of Medicine Publishes Case Reports on the Investigational Use of Soliris(R) (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Thursday, January 29, 2009
Alexion Pharmaceuticals To Report Fourth Quarter and Full Year 2008 Results on February 12, 2009

Monday, January 12, 2009
Soliris(R) Receives Orphan Drug Designation in Japan

Monday, January 12, 2009
Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute

Monday, January 5, 2009
Alexion to Present at the 27th Annual JP Morgan Healthcare Conference

Monday, January 5, 2009